Skip to main
  1. Stocks
  2. Greenwich Lifesciences
  3. Forecast
GLSI

Greenwich Lifesciences (GLSI) Stock Forecast & Price Target

Greenwich Lifesciences (GLSI) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Greenwich LifeSciences is viewed positively because its Phase III FLAMINGO-01 program is generating encouraging efficacy and immune-response signals, including a 70–80% recurrence reduction in the fully enrolled 247-patient non-HLA-A*02 arm and a DTH increase from 5.2% to 20.4% in 191 patients. The recent FDA and EMA protocol changes that combine HLA types in the randomized arms, plus UK expansion, broaden eligibility to about 55% more patients and could lift enrollment by up to 122%, improving event accrual and shortening the path to interim readouts. Despite a 3Q26 net loss of $5.8M, or ($0.40) per share, these operational catalysts, along with two SABCS 2026 abstracts and posters on December 9, 2026, support a more favorable fundamental outlook.

Bears say

Greenwich LifeSciences is facing a weak fundamental setup because it had only $5.9M in cash at the end of September 2026 while operating cash burn was ($3.0M) in 3Q26, leaving limited liquidity to support day-to-day operations. The company also appears dependent on capital markets, since additional funding is needed within the next 12 months and management expects to raise capital through the sale of equity and/or debt securities. That financing need, combined with the ongoing FLAMINGO-01 trial, raises dilution and balance-sheet risk and underscores a stretched funding profile for a clinical-stage biopharmaceutical company.

Greenwich Lifesciences (GLSI) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Greenwich Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Greenwich Lifesciences (GLSI) Analyst Forecast & Price Prediction

Get the latest Greenwich Lifesciences (GLSI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Greenwich Lifesciences (GLSI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Greenwich Lifesciences (GLSI) Forecast

Analysts have given Greenwich Lifesciences (GLSI) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Greenwich Lifesciences (GLSI) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Greenwich Lifesciences (GLSI)


Greenwich Lifesciences (GLSI) Analyst Forecast & Price Prediction

Get the latest Greenwich Lifesciences (GLSI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Greenwich Lifesciences (GLSI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GLSI stock data and trends